GO Main Menu Go Main Contents Go Bottom Menu
  • Remsima®SC is the world's first SC formulation of biosimilar infliximab developed by Celltrion. It was approved by the European Medicines Agency (EMA) .

    Remsima®SC image
    • Product Name : Remsima®SC
    • INN :
    • Indications : Rheumatoid Arthritis(RA), Crohn’s disease(CD), Ulcerative Colitis(UC), Ankylosing Spondylitis(AS), Psoriatic Arthritis(PsA), Psoriasis in adult patients
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Europe

    This product description is for medical and educational purposes only. They are not intended to promote PR or sales campaigns. For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

  • Remsima® is the world's first biosimilar monoclonal antibody developed by Celltrion. It was approved by international drug regulatory agencies across about 110 countries including the European Medicines Agency(EMA) and the U.S. Food and Drug Administration(FDA).

    Remsima® image
    • Product Name : Remsima® / U.S. Product Name : Inflectra®
    • INN : Infliximab
    • Indications : Rheumatoid Arthritis(RA), Ankylosing Spondylitis(AS), Ulcerative Colitis(UC), Crohn’s disease(CD), Psoriatic Arthritis(PsA), Psoriasis
    • Protein Type : Monoclonal antibody (mAb)
    • Mechanism of Action : It slows down the disease progression by neutralizing tumor necrosis factor-alpha (TNF-a), which is a common cause of autoimmune diseases.
    • Drug Approval Status : Europe, USA, Canada, the Republic of Korea, Japan, etc.

    This product description is for medical and educational purposes only. They are not intended to promote PR or sales campaigns. For more details, please consult a doctor or a medical specialist. This site is intended for all over the world.

Cookie technology helps us bring you the best possible experience when you visit this website. If you continue without changing your settings, you are agreeing to the cookies on this website. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.